title: Neuroleptic malignant syndrome during abrupt reduction of neuroleptic treatment.
abstract: Development of neuroleptic malignant syndrome (NMS) following discontinuation of high-dose and high-potency neuroleptic agents is described. This case, although rare and atypical, should alert clinicians to consider the possibility of NMS as a complication of abrupt neuroleptic drug withdrawal. It is suggested that dopaminergic imbalance, as opposed to excessive dopaminergic blockade, may also play a role in the precipitation of NMS.
authors.affiliation: Gehah Psychiatric Hospital, Beilinson Medical Center, Petah Tiqva, Israel.
authors.forename: B
authors.initials: B
authors.lastname: Spivak
authors.forename: A
authors.initials: A
authors.lastname: Weizman
authors.forename: L
authors.initials: L
authors.lastname: Wolovick
authors.forename: H
authors.initials: H
authors.lastname: Hermesh
authors.forename: S
authors.initials: S
authors.lastname: Tyano
authors.forename: H
authors.initials: H
authors.lastname: Munitz
mesh_terms: D000293:Adolescent; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002746:Chlorpromazine / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006220:Haloperidol / Q000009:adverse effects; D006801:Humans; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology*; D011618:Psychotic Disorders / Q000188:drug therapy*; D013375:Substance Withdrawal Syndrome / Q000209:etiology*; D014282:Trihexyphenidyl / Q000009:adverse effects
chemical_list: D014150:Antipsychotic Agents; D014282:Trihexyphenidyl; D006220:Haloperidol; D002746:Chlorpromazine